Gilad Oren's Form 4 filing
Aprea Therapeutics, Inc. (APRE) · filed Oct 15, 2024
- Accession no.
- 0001104659-24-108375
- Filed
- Oct 15, 2024
- Trade date
- Oct 10-14, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $2.97K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gilad OrenCIK 0001929300 | Director, Officer (President/CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 10, 2024 | Common Stock | PPurchaseAcquired | +150 | $2.54 | +$381 | 331,645 | Direct | |
| Oct 14, 2024 | Common Stock | PPurchaseAcquired | +1,000 | $2.59 | +$2,590 | 332,645 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.